▶ ORAL GLP-1 RECEPTOR MIMETIC · SUBTOPIC · SAFETY PROFILE
ORAL GLP-1 RECEPTOR MIMETIC Safety Profile
For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of ORAL GLP-1 RECEPTOR MIMETIC.
OBSERVED ADVERSE EVENTS IN LITERATURE
The following adverse events have been observed in trials or animal studies of ORAL GLP-1 RECEPTOR MIMETIC. Severity, frequency, and attribution depend on the source publication.
- GI: nausea, diarrhea, vomiting (titration-dependent)
- Decreased appetite
DRUG INTERACTIONS
The following interactions are reported in or theorised from the published mechanism for ORAL GLP-1 RECEPTOR MIMETIC.
- Standard GLP-1 class · oral medication absorption (delayed gastric emptying)
CONTRAINDICATIONS REPORTED IN LITERATURE
Contraindications recorded for ORAL GLP-1 RECEPTOR MIMETIC in the published record:
- History of MTC or MEN2 (class precaution)
FDA REGULATORY STATUS
Investigational. Phase 3 ACHIEVE/ATTAIN programs ongoing.
WADA REGULATORY STATUS
Not currently listed on the WADA Prohibited List.
SAFETY Q+A FROM LITERATURE
▶ Is the oral GLP-1 receptor mimetic FDA-approved?
Not yet as of 2026-05. Phase 3 ACHIEVE-1 (T2D) and ATTAIN-1 (obesity) programs are ongoing.
CITED LITERATURE
The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.
- Wharton S, et al.. Daily Oral GLP-1 Receptor Agonist the oral GLP-1 receptor mimetic for Adults with Obesity. N Engl J Med 2023. PMID 37364188. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19